Opportunities for nanotheranosis in lung cancer and pulmonary metastasis

被引：17
作者：
Key J. [1 ]
Kim Y.-S. [1 ]
Tatulli F. [2 ]
Palange A.L. [1 ]
O’Neill B. [1 ]
Aryal S. [1 ]
Ramirez M. [1 ]
Liu X. [3 ]
Ferrari M. [3 ]
Munden R. [4 ]
Decuzzi P. [1 ,5 ]
机构：
[1] Department of Translational Imaging, Houston Methodist Research Institute, Houston, 77030, TX
[2] PET Center, Houston Methodist Research Institute, Houston, 77030, TX
[3] Department of Nanomedicine, Houston Methodist Research Institute, Houston, 77030, TX
[4] Department of Radiology, Houston Methodist Hospital, Houston, 77030, TX
[5] Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, Genoa
来源：
Clinical and Translational Imaging | 2014年 / 2卷 / 5期
基金：
欧洲研究理事会; 美国国家卫生研究院;
关键词：
Multi-modal imaging; Nanomedicine; Nanoparticles;
D O I：
10.1007/s40336-014-0078-7
中图分类号：
学科分类号：
摘要：
Malignancies of the lungs, both primary and metastatic, are the leading cause of death worldwide. Over 1.5 million new cases of primary lung cancer are diagnosed annually worldwide with a dismal 5-year survival rate of approximately 15 %, which remains unchanged despite major efforts and medical advances. As expected, survival for patients with lung metastases is even worse at about 5 %. Early detection and staging are fundamental in improving survival rates and selecting the most effective treatment strategies. Recently, nanoparticles have been developed for imaging and treating various cancers, including pulmonary malignancies. In this work, three different examples of nanoparticle configurations for cancer theranosis are presented, namely conventional spherical polymeric nanoparticles with a diameter of ~150 nm; and discoidal mesoporous silicon nanoconstructs and discoidal polymeric nanoconstructs with a diameter of ~1,000 nm and a height of 400 and 500 nm, respectively. The spherical nanoparticles accumulate in tumors by means of the well-known enhanced permeation and retention effect, whereas sub-micrometer discoidal nanoconstructs are rationally designed to adhere firmly to the tortuous tumor vasculature. All three nanoparticles are characterized for their in vivo performance in terms of magnetic resonance, positron-emission tomography (PET), and optical imaging. Preliminary data on the in vivo and ex vivo PET/CT imaging of breast cancer metastasis in the lungs using discoidal nanoconstructs is presented. In conclusion, opportunities for nanoparticle-based theranosis in primary lung cancer and pulmonary metastasis are presented and discussed. © 2014, Italian Association of Nuclear Medicine and Molecular Imaging.
引用
收藏
页码：427 / 437
页数：10
相关论文
共 34 条
[1]  
Fact sheet No 297, World Health Organization, (2013)
[2]  
The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer, J Thorac Oncol, 2, pp. 593-602, (2007)
[3]  
Murphy S.L., Xu J., Kochanek K.D., National vital statistics report. Deaths: final data for 2010, Centers for Disease Control and Prevention, 61, 4, (2013)
[4]  
Howlader N., Noone A.M., Krapcho M., Garshell J., Neyman N., Altekruse S.F., Kosary C.L., Yu M., Ruhl J., Tatalovich Z., Cho H., Mariotto A., Lewis D.R., Chen H.S., Feuer E.J., Cronin K.A., SEER cancer statistics review, (2013)
[5]  
Mohammed T.L., Chowdhry A., Reddy G.P., Amorosa J.K., Brown K., Dyer D.S., Ginsburg M.E., Heitkamp D.E., Jeudy J., Kirsch J., MacMahon H., Parker J.A., Ravenel J.G., Saleh A.G., Shah R.D., Expert panel on thoracic imaging, screening for pulmonary metastases. J Thorac Imaging, 26, pp. W1-W3, (2011)
[6]  
Non-small cell lung cancer clinical practice guidelines in oncology, J Natl Compr Canc Netw, 4, 6, pp. 548-582, (2006)
[7]  
National Lung Screening Trial Research Team, Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., Sicks J.D., Reduced lung-cancer mortality with low-dose computed tomographic screening, N Engl J Med, 365, pp. 395-409, (2011)
[8]  
Lynch T.J., Bogart J.A., Curran W.J., DeCamp M.M., Gandara D.R., Goss G., Henschke C.I., Jett J.R., Johnson B.E., Kelly K.L., Le Chevalier T., Mulshine J.L., Scagliotti G.V., Schiller J.H., Shaw A., Thatcher N., Vokes E.E., Wood D.E., Hart C., Early stage lung cancer—new approaches to evaluation and treatment: conference summary statement, Clin Cancer Res, 11, 13 Pt 2, pp. 4981s-4983s, (2005)
[9]  
Lardinois D., Weder W., Hany T.F., Kamel E.M., Korom S., Seifert B., von Schulthess G.K., Steinert H.C., Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography, N Engl J Med, 348, pp. 2500-2507, (2003)
[10]  
Vansteenkiste J.F., Stroobants S.G., Positron emission tomography in the management of non-small cell lung cancer, Hematol Oncol Clin North Am, 18, pp. 269-288, (2004)
1234